$22 Million Invested in Inimex Pharma

Inimex Pharmaceuticals, based in Vancouver, BC, has announced that it has closed a $22 million Series B venture round, led by Morningside Venture Investments. Inimex is focused on discovering and developing new medicines based on selective modulation of the innate immune response. The funds will help the company conduct the first clinical trials of an innate defense regulator drug.

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and Editor of Xconomy Boston. E-mail him at gthuang [at] xconomy.com. Follow @gthuang

Trending on Xconomy